{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:19:25Z","timestamp":1786123165566,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01561-4","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:16:01Z","timestamp":1786112161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Capmatinib for High-Level MET-Amplified Metastatic Gastric Cancer Identified by Comprehensive Genomic Profiling: A Case Report and Literature Review"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8694","authenticated-orcid":false,"given":"Yasuyoshi","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurina","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"1561_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654\u201364.","journal-title":"Lancet"},{"key":"1561_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","volume":"18","author":"DVT Catenacci","year":"2017","unstructured":"Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1467\u201382.","journal-title":"Lancet Oncol"},{"key":"1561_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","volume":"3","author":"MA Shah","year":"2017","unstructured":"Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric randomized clinical trial. JAMA Oncol. 2017;3:620\u20137.","journal-title":"JAMA Oncol"},{"key":"1561_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"1561_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10120-015-0585-x","volume":"19","author":"H Kawakami","year":"2016","unstructured":"Kawakami H, Okamoto I. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer. 2016;19:687\u201395.","journal-title":"Gastric Cancer"},{"key":"1561_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40291-021-00568-w","volume":"26","author":"Y Dong","year":"2022","unstructured":"Dong Y, Xu J, Sun B, Wang J, Wang Z. MET-targeted therapies and clinical outcomes: a systematic literature review. Mol Diagn Ther. 2022;26:203\u201327.","journal-title":"Mol Diagn Ther"},{"key":"1561_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cas.14254","volume":"111","author":"YJ Bang","year":"2020","unstructured":"Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci. 2020;111:536\u201347.","journal-title":"Cancer Sci"},{"key":"1561_CR8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer. N Engl J Med. 2020;383:944\u201357.","journal-title":"N Engl J Med"},{"key":"1561_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/cas.16034","volume":"115","author":"Y Ando","year":"2024","unstructured":"Ando Y, Shimoi T, Sunami K, Okita N, Nakamura K, Shibata T, et al. Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial. Cancer Sci. 2024;115:555\u201363.","journal-title":"Cancer Sci"},{"key":"1561_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1561_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10147-020-01684-z","volume":"25","author":"S Iwasa","year":"2020","unstructured":"Iwasa S, Kudo T, Takahari D, Hara H, Kato K, Satoh T. Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int J Clin Oncol. 2020;25:1223\u201332.","journal-title":"Int J Clin Oncol"},{"key":"1561_CR12","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1535-7163.MCT-11-0934","volume":"11","author":"W Okamoto","year":"2012","unstructured":"Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012;11:1557\u201364.","journal-title":"Mol Cancer Ther"},{"issue":"36","key":"1561_CR13","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","volume":"29","author":"JK Lennerz","year":"2011","unstructured":"Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803\u201310.","journal-title":"J Clin Oncol"},{"key":"1561_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11523-021-00811-8","volume":"16","author":"T Aparicio","year":"2021","unstructured":"Aparicio T, Cozic N, de la Fouchardi\u00e8re C, et al. The activity of crizotinib in chemo-refractory MET-amplified esophageal and gastric adenocarcinomas: results from the AcS\u00e9-Crizotinib program. Target Oncol. 2021;16:381\u20138.","journal-title":"Target Oncol"},{"issue":"8","key":"1561_CR15","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-18-1337","volume":"25","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem E, Karaszewska B, Kang YK, Chung HC, Shankaran V, Siena S, et al. A multicenter phase II study of AMG 337 in patients with MET-amplified gastric\/gastroesophageal junction\/esophageal adenocarcinoma and other MET-amplified solid tumors. Clin Cancer Res. 2019;25(8):2414\u201323.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1561_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-0442","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee J, Kim ST, Kim K, Lee H, Kozarewa I, Mortimer PGS, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov. 2019;9(10):1388\u2013405.","journal-title":"Cancer Discov"},{"issue":"5","key":"1561_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/oncolo\/oyab066","volume":"27","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu T, Chen G, Gong J, Bai Y, Zhang T, et al. Phase Ia\/Ib study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, efficacy, and biomarkers. Oncologist. 2022;27(5):342\u2013e383.","journal-title":"Oncologist"},{"key":"1561_CR18","doi-asserted-by":"publisher","unstructured":"Peng Z, Liu T, Wang H, Wang J, Liu H, Ye F, et al. Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. 2026 Jun;1. https:\/\/doi.org\/10.1038\/s41591-026-04459-7.","DOI":"10.1038\/s41591-026-04459-7"},{"key":"1561_CR19","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-23-1217","volume":"14","author":"F Pecci","year":"2024","unstructured":"Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, et al. Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors. Cancer Discov. 2024;14:1440\u201356. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1217.","journal-title":"Cancer Discov"},{"key":"1561_CR20","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.eclinm.2024.102447","volume":"69","author":"T Shimoi","year":"2024","unstructured":"Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, et al. Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. eClinicalMedicine. 2024;69:102447.","journal-title":"eClinicalMedicine"},{"key":"1561_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/iju5.70093","volume":"8","author":"Y Sato","year":"2025","unstructured":"Sato Y, Fujii Y, Nakamura M, Tanai C, Yamada Y, Watanabe K, et al. A case of metastatic castration-resistant prostate cancer with RAD54L mutation responding to niraparib. IJU Case Rep. 2025;8:578\u201382.","journal-title":"IJU Case Rep"},{"key":"1561_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/PO.19.00386","volume":"4","author":"MM Frigault","year":"2020","unstructured":"Frigault MM, Markovets A, Nuttall B, Kim KM, Park SH, Gangolli EA, et al. Mechanisms of acquired resistance to savolitinib, a selective MET inhibitor in MET-amplified gastric cancer. JCO Precis Oncol. 2020;4:222\u201332. https:\/\/doi.org\/10.1200\/PO.19.00386.","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01561-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:16:02Z","timestamp":1786112162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01561-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01561-4","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"28 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the National Cancer Center Hospital Certified Review Board (approval number: CRB3180008). All patient data were anonymized before analysis and publication. Written informed consent was obtained from the patient for participation in this trial and the publication of this case report. Novartis Pharma K.K. provided capmatinib for this study.","order":1,"name":"Ethics","label":"Ethics and Regulatory Considerations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KW reports affiliation with an endowed chair funded by Konica Minolta, Inc. and GenMine Labs Corp.; research funding from Konica Minolta, Inc. and GenMine Labs Corp.; and lecture fees from GenMine Labs Corp. (formerly Konica Minolta REALM Inc.). MO reports affiliation with an endowed chair funded by Konica Minolta, Inc. and GenMine Labs Corp. KO reports research funding from Konica Minolta, Inc. and GenMine Labs Corp.; and lecture fees from GenMine Labs Corp. (formerly Konica Minolta REALM Inc.). Capmatinib used in this study was provided by Novartis Pharma K.K. under the BELIEVE trial framework. The authors declare no other conflicts of interest related to this work.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) and Claude (Anthropic) for language editing, proofreading, and readability improvement. These tools were not used to generate clinical data, analyze results, create figures, or draw scientific conclusions. After using these tools, the authors reviewed and edited the content as required and took full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"Use of Generative AI Tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The BELIEVE trial (NCCH1901; jRCTs031190104)","order":4,"name":"Ethics","label":"Trial Registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"180"}}